Zolmitriptan niosomal transdermal patches: combating migraine via epigenetic and endocannabinoid pathways and reversal of migraine hypercoagulability
Drug Delivery and Translational Research · 2025-06 · 15 (6) · 2179-2199
DOI: 10.1007/s13346-024-01731-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 05.11.2024. Verfasst von Nancy Abdel Hamid Abou Youssef und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical technology, Faculty of Pharmacy, Pharos University in Alexandria, Canal El Mahmoudia street, beside Gr…. Hauptthemen laut MEDLINE: Migraine Disorders, Tryptamines, Endocannabinoids, Oxazolidinones. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pharos University.
Abstract (Originalsprache)
Conventional zolmitriptan (ZOL) has limited oral bioavailability, many adverse effects, and poor membrane penetrability that negatively influences its accessibility to its 5-HT 1B/1D receptor binding pocket, located transmemberanous. This work aimed at preparing transdermal ZOL-nanoformulation (niosomes) to surpass these limitations and to explore novel antimigraine mechanisms for ZOL via modulation of the epigenetically-altered chronification genes (RAMP-1, NPTX-2) or microRNAs and affecting the endocannabinoid CB-1/MAPK pathway. The prepared ZOL niosomes (F sp60/6−1:1 ) exhibited %EE of 57.28%, PS of 472.3 nm, PDI of 0.366, and ZP of -26 mV were cast into patch with content uniformity of 93.12%, maintained endurance after 200-times folding, no interaction between its components (FT-IR), a biphasic release pattern and good stability after storage at 4 °C for 6 months. In-vivo ZOL-patch application in rats with nitroglycerin-induced migraine showed significant management of migraine pain symptoms and photophobia assessed behaviorally, decreased brain levels of the trigeminal neuronal activation marker (c-fos), the migraine pain neurotransmitter (CGRP) and the serum levels of different migraine pain markers (substance P, nitric-oxide, and TNF-α). It also significantly decreased RAMP-1, NPTX-2, miR-382-5p, and CB-1/MAPK gene expression reflecting improved efficacy and brain receptors delivery to a much greater extent than conventional ZOL has done. Additionally, this nanoformulation significantly opposed migraine-induced platelet activation and hypercoagulable status in both central and peripheral circulations as evidenced by the significant decrease in adenosine diphosphate, thrombin, factor X, CD41, and Von-Willebrand factor levels assessed peripherally and centrally. TPF sp60/6−1:1 significantly improved ZOL efficacy and accessibility to brain-receptors to a much greater extent than conventional ZOL-solution. KeywordsEndocannabinoid receptors; Epigenetically-altered genes; Hemostatic pathways; Niosomal patch; Transdermal; Zolmitriptan Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics and Pharmaceutical technology, Faculty of Pharmacy, Pharos University in Alexandria, Canal El Mahmoudia street, beside Green Plaza Complex , Alexandria, 21648, Egypt.
- Faculty of Pharmacy, Alamein International University, Alamein, Matrouh, 51718, Egypt.
- Department of Pharmaceutics and Pharmaceutical technology, Faculty of Pharmacy, Pharos University in Alexandria, Canal El Mahmoudia street, beside Green Plaza Complex , Alexandria, 21648, Egypt. abeer.kassem@pua.edu.eg.
- Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria, 21648, Egypt.
ORCID-Profile: Nancy Abdel Hamid Abou Youssef, Gihan Salah Labib, Abeer Ahmed Kassem, Nesrine S El-Mezayen
Förderung
- Pharos University
Zitieren
APA
Abou Youssef, N. A. H., Labib, G. S., Kassem, A. A., & El-Mezayen, N. S. (2025). Zolmitriptan niosomal transdermal patches: combating migraine via epigenetic and endocannabinoid pathways and reversal of migraine hypercoagulability. Drug Delivery and Translational Research, 15(6), 2179-2199. https://doi.org/10.1007/s13346-024-01731-6
Vancouver
Abou Youssef NAH, Labib GS, Kassem AA, El-Mezayen NS. Zolmitriptan niosomal transdermal patches: combating migraine via epigenetic and endocannabinoid pathways and reversal of migraine hypercoagulability. Drug Delivery and Translational Research. 2025;15(6):2179-2199. doi:10.1007/s13346-024-01731-6
BibTeX
@article{AbouYoussef2025,
author = {Abou Youssef, Nancy Abdel Hamid and Labib, Gihan Salah and Kassem, Abeer Ahmed and El-Mezayen, Nesrine S},
title = {Zolmitriptan niosomal transdermal patches: combating migraine via epigenetic and endocannabinoid pathways and reversal of migraine hypercoagulability},
journal = {Drug Delivery and Translational Research},
year = {2025},
volume = {15},
number = {6},
pages = {2179--2199},
doi = {10.1007/s13346-024-01731-6}
}
EUVIMED